Treatment of Refractory Antibody-mediated Rejection with Bortezomib in a Kidney Transplant Recipient: A Case Report.
10.4285/jkstn.2014.28.2.87
- Author:
Ji Yeon LEE
1
;
Jin Young YOO
;
Soon Hyo KWON
;
Jin Seok JEON
;
Hyunjin NOH
;
Dong Cheol HAN
;
Dan SONG
;
So Young JIN
Author Information
1. Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. jeonjs@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Proteasome inhibitors;
Antibody-mediated rejection;
Kidney transplantation
- MeSH:
Allografts;
Antibodies;
Antilymphocyte Serum;
Bortezomib;
Creatinine;
Humans;
Immunoglobulins;
Kidney Transplantation;
Kidney*;
Middle Aged;
Multiple Myeloma;
Plasmapheresis;
Proteasome Inhibitors;
Rituximab;
Tissue Donors;
Transplantation*;
Transplants
- From:The Journal of the Korean Society for Transplantation
2014;28(2):87-90
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Antibody-mediated rejection (ABMR) is associated with poor renal allograft survival. It shows poor response to conventional treatment with plasmapheresis, rituximab, and intravenous immunoglobulin. Bortezomib, a proteasome inhibitor used for treatment of multiple myeloma, has recently been reported as a treatment alternative for recipient desensitization and ABMR. A 58-year-old man was diagnosed with mixed-type ABMR with donor specific antibodies and acute T cell-mediated rejection early after kidney transplantation. Conventional therapy was administered, including antithymocyte globulin, plasmapheresis, and rituximab; however, his condition was found to be refractory to these antihumoral therapies. Following administration of bortezomib, his serum creatinine level returned to baseline with stable graft function. His serum creatinine level remains stable at 1.3 mg/dL at 10 months posttransplantation. Bortezomib is effective for treatment of refractory ABMR following kidney transplantation.
